Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Yutaka Ogihara | President, CEO & Chairman | -- | -- | 1967 |
| Yasuji Kurose | CFO, CStO, Director of Corporate Planning & Executive Director | -- | -- | -- |
| Junichi Ishiyama | Executive Officer, Chief Scientific Officer & GM of Drug Discovery Division | -- | -- | -- |
| Kiyoo Uehara | Executive Officer, Chief Human Resource Officer & Director of General Affairs | -- | -- | -- |
| Mr. Michiro Onota | Executive Director & CMO | -- | -- | 1960 |
| Takaaki Kaji | Executive Officer & Chief Business Development Officer | -- | -- | -- |
| Noriaki Tamura | Executive Officer, Chief Commercial Officer & GM of Pharmaceutical Sales Division | -- | -- | -- |
| Kimiya Masada | Corporate Officer & Director of Product Strategy | -- | -- | -- |
| Mr. Hiroshi Hashizume | Executive Officer, President & Representative Director of Kyorin Rimedio Co., Ltd. | -- | -- | -- |
| Dr. Makoto Yanai Ph.D. | Executive Officer & Deputy GM of Business Development Division | -- | -- | -- |
KYORIN Pharmaceutical Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 2,042
Description
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
Corporate Governance
Upcoming Events
May 12, 2025 at 6:00 AM UTC
KYORIN Pharmaceutical Co., Ltd. Earnings Date
Recent Events
March 28, 2025 at 12:00 AM UTC
Ex-Dividend Date